Trial Profile
A retrospective study of interrupted BRAFi (Vemurafenib and Dabrafenib) versus concomitant radiotherapy in melanoma patients
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 16 Feb 2018
Price :
$35
*
At a glance
- Drugs Dabrafenib (Primary) ; Vemurafenib (Primary)
- Indications Malignant melanoma
- Focus Adverse reactions; Therapeutic Use
- 16 Feb 2018 New trial record
- 13 Feb 2018 Results assessing efficacy and safety of BRAFi interrupted versus concomitant therapy during radiotherapy published in the British Journal of Cancer.